4.5 Article

Sustained postoperative anaemia is associated with an impaired outcome after coronary artery bypass graft surgery: insights from the IMAGINE trial

Journal

HEART
Volume 97, Issue 19, Pages 1590-1596

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/heartjnl-2011-300118

Keywords

-

Funding

  1. Pfizer Canada
  2. Pfizer, The Netherlands
  3. Pfizer, Belgium
  4. Pfizer, France

Ask authors/readers for more resources

Objective To investigate the association between sustained postoperative anaemia and outcome after coronary artery bypass graft (CABG) surgery. Design Retrospective analysis of the IMAGINE trial, which tested the effect of the ACE inhibitor quinapril on cardiovascular events after CABG. Setting Thoracic surgery clinic/outpatient department. Patients 2553 stable patients with left ventricular ejection fraction >40% 2-7 days after scheduled CABG. Interventions Randomisation to quinapril or placebo. Main outcome measures Cox regression analysis for the association between postoperative anaemia and cardiovascular events and the effect of quinapril on the incidence of anaemia. Results Postoperative anaemia was sustained for >50 days in 44% of patients. Sustained postoperative anaemia was associated with an increased incidence of cardiovascular events during the first 3 months (adjusted HR (adjHR) 1.77, 95% CI 1.10 to 2.85, p=0.012) and during the maximum follow-up of 43 months (adjHR 1.37, 95% CI 1.14 to 1.65, p=0.008). When haemoglobin (Hb) was considered as a continuous variable, every 1 mg/dl decrease in Hb was associated with a 13% increase in cardiovascular events (adjHR 0.87, 95% CI 0.81 to 0.95, p=0.003) and a 22% increase in all-cause mortality (adjHR 0.78, 95% CI 0.60 to 0.99, p=0.034). Quinapril was associated with a slower postoperative recovery of Hb levels and a higher incidence of cardiovascular events in patients with anaemia (adjHR 1.60, 95% CI 1.1 to 2.4, p=0.024). Conclusions Postoperative anaemia is common, frequently persists for months after CABG surgery and is associated with an impaired outcome. In patients with anaemia, ACE inhibitors slowed recovery from postoperative anaemia and increased the incidence of cardiovascular events after CABG.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers

Canxia Shi, Joseph Pierre Aboumsallem, Navin Suthahar, Aniek O. de Graaf, Joop H. Jansen, Isabelle A. van Zeventer, Valentina Bracun, Sanne de Wit, Elles M. Screever, Pieter F. van den Berg, Wouter C. Meijers, Ron T. Gansevoort, Stephan J. L. Bakker, Pim van der Harst, Herman H. W. Sillje, Gerwin Huls, Rudolf A. de Boer

Summary: This study aimed to analyze the association between clonal hematopoiesis of indeterminate potential (CHIP) and incident heart failure (HF) in a European population cohort. Results showed that CHIP mutations were correlated with age, smoking, hypertension, and cardiovascular biomarkers, but the frequency of CHIP was similar between individuals with incident HF and control participants. However, among people younger than 65 years, CHIP mutations were more frequently detected in the case cohort and significantly associated with new-onset HF.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Article Cardiac & Cardiovascular Systems

Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial

S. N. Voorrips, E. M. Boorsma, J. C. Beusekamp, R. A. DE -boer, M. A. Connelly, R. P. F. Dullaart, P. Van-der-meer, D. J. Van-veldhuisen, A. A. Voors, K. Damman, B. D. Westenbrink

Summary: This study analyzed the ketone body production in patients with acute decompensated heart failure and found that ketone body concentrations were significantly increased during acute decompensation. However, treatment with empagliflozin had no significant effect on ketone body concentrations. These findings provide insights into the metabolic characteristics of acute heart failure.

JOURNAL OF CARDIAC FAILURE (2023)

Editorial Material Cardiac & Cardiovascular Systems

Growth differentiation factor 15: a biomarker searching for an indication

Christian Mueller, Tamar S. Muench-Gerber, Rudolf A. de Boer

EUROPEAN HEART JOURNAL (2023)

Article Medicine, General & Internal

Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population

Navin Suthahar, Kan Wang, Victor W. Zwartkruis, Stephan J. L. Bakker, Silvio E. Inzucchi, Tim R. Eijgenraam, Fariba Ahmadizar, Eric G. Sijbrands, Ron T. Gansevoort, Lyanne M. Kieneker, Dirk J. van Veldhuisen, Maryam Kavousi, Rudolf A. de Boer

Summary: Relative fat mass (RFM), a novel anthropometric equation based on height and waist measurements, is strongly associated with incident type-2 diabetes (T2D) and shows potential as a predictor of future diabetes risk in the general population, outperforming BMI, waist circumference, and waist-to-hip ratio.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum

Jawad H. Butt, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, James C. Fang, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Jose Walter Cabrera Honorio, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Lars Kober, Carolyn S. P. Lam, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Orly Vardeny, Eileen O'Meara, Jose F. K. Saraiva, Sanjiv J. Shah, Muthiah Vaduganathan, Pardeep S. Jhund, Scott D. Solomon, John J. V. McMurray

Summary: Black people have a higher incidence and prevalence of heart failure than White people, and they may have worse outcomes once HF has developed. This study examined the outcomes and response to treatment with dapagliflozin in Black and White patients with heart failure. The results showed that dapagliflozin had consistent benefits in both Black and White patients, with greater absolute benefits in Black patients.

JACC-HEART FAILURE (2023)

Article Cardiac & Cardiovascular Systems

Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER

Jawad H. Butt, Toru Kondo, Mingming Yang, Pardeep S. Jhund, Kieran F. Docherty, Muthiah Vaduganathan, Brian L. Claggett, Adrian F. Hernandez, Carolyn S. P. Lam, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Mikhail N. Kosiborod, Akshay S. Desai, Lars Kober, Piotr Ponikowski, Marc S. Sabatine, Sanjiv J. Shah, Natalia Zaozerska, Ulrica Wilderang, Olof Bengtsson, Scott D. Solomon, John J. McMurray

Summary: This study aimed to assess the efficacy and safety of dapagliflozin in patients with heart failure, particularly in those with peripheral artery disease (PAD). The results showed that dapagliflozin was equally effective in patients with and without PAD and did not increase the risk of amputation.

EUROPEAN HEART JOURNAL (2023)

Article Cardiac & Cardiovascular Systems

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Safia Chatur, Muthiah Vaduganathan, Brian Claggett, Orly Vardeny, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer, Carolyn S. P. Lam, Mikhail N. Kosiborod, Sanjiv J. Shah, Felipe Martinez, Silvio E. Inzucchi, Adrian F. Hernandez, Tariq Haddad, Sumeet S. Mitter, Zi Michael Miao, Magnus Petersson, Anna Maria Langkilde, John J. McMurray, Scott D. Solomon

Summary: In this study, the safety and efficacy of dapagliflozin were evaluated according to different diuretic therapies and its influence on diuretic use. The results showed that dapagliflozin had consistent clinical benefits in terms of reducing heart failure worsening and cardiovascular death across different diuretic categories and doses, with a similar safety profile. Dapagliflozin also significantly reduced the need for loop diuretics over time.

EUROPEAN HEART JOURNAL (2023)

Article Cardiac & Cardiovascular Systems

Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials

Ankeet S. Bhatt, Mikhail N. Kosiborod, Muthiah Vaduganathan, Brian L. Claggett, Z. Michael Miao, Ian J. Kulac, Carolyn S. P. Lam, Adrian F. Hernandez, Felipe Martinez, Silvio E. Inzucchi, Sanjiv J. J. Shah, Rudolf A. de Boer, Pardeep S. Jhund, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, John J. V. McMurray, Scott D. Solomon

Summary: In this study, the effects of dapagliflozin on health status in heart failure patients were examined. The results showed that dapagliflozin improved health status in patients across the full range of left ventricular ejection fraction (LVEF).

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Article Cardiac & Cardiovascular Systems

Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers

Mark Jansen, A. F. Schmidt, J. J. M. Jans, I. Christiaans, S. N. van der Crabben, Y. M. Hoedemaekers, D. Dooijes, J. D. H. Jongbloed, L. G. Boven, R. H. Lekanne Deprez, A. A. M. Wilde, J. van der Velden, R. A. de Boer, J. P. van Tintelen, F. W. Asselbergs, A. F. Baas

Summary: In this study, acylcarnitines were evaluated as potential biomarkers for hypertrophic cardiomyopathy (HCM). The study found that several acylcarnitines were significantly increased in patients with severe HCM, and some were also increased in patients with mild HCM. Additionally, certain acylcarnitines were associated with measures of HCM severity. Prospective studies are needed to further investigate the prognostic value of these biomarkers.

JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2023)

Article Cardiac & Cardiovascular Systems

Micronutrient deficiencies and new-onset atrial fibrillation in a community-based cohort: data from PREVEND

Ali A. A. Al-Mubarak, Niels Grote Beverborg, Victor Zwartkruis, Colinda van Deutekom, Martin H. H. de Borst, Ron T. T. Gansevoort, Stephan J. L. Bakker, Daan J. J. Touw, Rudolf A. A. de Boer, Peter van der Meer, Michiel Rienstra, Nils Bomer

Summary: This study aimed to investigate the association between micronutrient deficiencies and the development of atrial fibrillation (AFib). Selenium deficiency was found to be associated with new-onset AFib in non-smoking participants.

CLINICAL RESEARCH IN CARDIOLOGY (2023)

Article Oncology

Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure

Pieter F. van den Berg, Joseph Pierre Aboumsallem, Elles M. Screever, Canxia Shi, Sanne de Wit, Valentina Bracun, Laura I. Yousif, Lotte Geerlings, Dongyu Wang, Jennifer E. Ho, Stephan J. L. Bakker, Bert van der Vegt, Herman H. W. Sillje, Rudolf A. de Boer, Wouter C. Meijers

Summary: The fibrosis-related biomarker galectin-3 (gal-3) is associated with new-onset cancer and heart failure (HF) in males, but not in females.

JACC: CARDIOONCOLOGY (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

Circulating vascular cell adhesion molecule level is an independent predictor of adverse outcomes in HFrEF: findings from DAPA-HF

K. Mcdowell, P. Welsh, K. Docherty, D. A. Morrow, R. A. De Boer, E. O'meara, S. E. Inzucchi, L. Kober, M. N. Kosiborod, F. A. Martinez, A. M. Langkilde, S. D. Solomon, N. Sattar, M. S. Sabatine, J. J. V. Mcmurray

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

Sexual dimorphism in heart failure: targeting the sex-specific fibrotic response

L. M. G. Laura Marieke Gezina Meems, S. Li, G. Krenning, C. J. Boogerd, H. H. W. Sillje, C. Withaar, R. A. De Boer

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

Efficacy and safety of dapagliflozin in the background of polypharmacy among patients with HFmrEF and HFpEF in the DELIVER trial

Peikert, P. Goyal, M. Vaduganathan, B. L. Claggett, A. S. Desai, P. S. Jhund, M. N. Kosiborod, C. S. P. Lam, S. E. Inzucchi, F. A Martinez, R. A. De Boer, A. F. Hernandez, S. J. Shah, J. J. V. Mcmurray, S. D. Solomon

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

Proteomic biomarkers related to obesity in heart failure patients and their associations with mortality

T. B. Petersen, N. Suthahar, F. W. Asselbergs, M. De Bakker, K. M. Akkerhuis, A. A. Constantinescu, J. Van Ramshorst, P. D. Katsikis, P. J. Van Der Spek, V. A. Umans, R. A. De Boer, E. Boersma, D. Rizopoulos, I. Kardys

EUROPEAN JOURNAL OF HEART FAILURE (2023)

No Data Available